BRPI0519508A2 - análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase - Google Patents

análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase

Info

Publication number
BRPI0519508A2
BRPI0519508A2 BRPI0519508-0A BRPI0519508A BRPI0519508A2 BR PI0519508 A2 BRPI0519508 A2 BR PI0519508A2 BR PI0519508 A BRPI0519508 A BR PI0519508A BR PI0519508 A2 BRPI0519508 A2 BR PI0519508A2
Authority
BR
Brazil
Prior art keywords
glaucoma
treatment
rho kinase
conditions
aminopyrazine
Prior art date
Application number
BRPI0519508-0A
Other languages
English (en)
Inventor
Alan J Henderson
Cheng Guo
Mark Hadden
Hel N Y Decornez
Mark R Hellberg
Andrew Rusinko
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BRPI0519508A2 publication Critical patent/BRPI0519508A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

ANáLOGOS DE AMINOPIRAZINA PARA TRATAMENTO DE GLAUCOMA E OUTRAS DOENçAS OU CONDIçOES MEDIADAS POR RHO CINASE. A presente invenção refere-se a métodos para emprego de análogos de aminopirazina para tratar doenças mediadas por rho cinase ou condições mediadas por rho cinase, incluindo o controle da pressão intraocular e tratamento de glaucoma. São descritas também composições farmacéuticas oftálmicas úteis no tratamento de doenças oculares tais como glaucoma, e adicionalmente úteis para o controle de pressão intra-ocular, as composições compreendendo uma quantidade eficaz de análogos de aminopi razina.
BRPI0519508-0A 2004-12-27 2005-12-14 análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase BRPI0519508A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63938904P 2004-12-27 2004-12-27
PCT/US2005/045384 WO2006071548A2 (en) 2004-12-27 2005-12-14 Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases

Publications (1)

Publication Number Publication Date
BRPI0519508A2 true BRPI0519508A2 (pt) 2009-03-17

Family

ID=36615388

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519508-0A BRPI0519508A2 (pt) 2004-12-27 2005-12-14 análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase

Country Status (17)

Country Link
US (2) US20080269249A2 (pt)
EP (1) EP1830853B1 (pt)
JP (1) JP2008525453A (pt)
KR (1) KR100994173B1 (pt)
CN (1) CN101102773B (pt)
AR (1) AR053110A1 (pt)
AT (1) ATE519488T1 (pt)
AU (1) AU2005322338B2 (pt)
BR (1) BRPI0519508A2 (pt)
CA (1) CA2590261C (pt)
ES (1) ES2368338T3 (pt)
HK (1) HK1104222A1 (pt)
MX (1) MX2007007797A (pt)
PL (1) PL383491A1 (pt)
TW (1) TW200633709A (pt)
WO (1) WO2006071548A2 (pt)
ZA (1) ZA200704959B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200710379B (en) 2005-05-20 2009-05-27 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
MX2008008328A (es) * 2005-12-22 2008-09-15 Alcon Res Ltd (indazol-5-il)-pirazinas y (1,3-dihidro-indol-2-ona)-pirazinas para tratar enfermedades y condiciones mediadas con rho cinasa.
AR060336A1 (es) 2006-03-31 2008-06-11 Schering Corp Derivados de indazolilpirazinilo inhibidores de proteinquinasas, composiciones farmaceuticas que los contienen y usos como agentes anticancer,entre otros.
US20080021217A1 (en) * 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
PL2084162T3 (pl) 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Bicykliczne triazole jako modulatory kinaz białkowych
CN101616587A (zh) * 2006-12-05 2009-12-30 孙仲铭 吲唑化合物
EP2167491A1 (en) * 2007-06-08 2010-03-31 Abbott Laboratories 5-heteroaryl substituted indazoles as kinase inhibitors
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
KR101712576B1 (ko) 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
PT2376485T (pt) 2008-12-19 2018-03-12 Vertex Pharma Derivados de pirazina úteis como inibidores da cinase atr
US8513271B2 (en) * 2009-10-30 2013-08-20 Janssen Pharmaceutica, Nv Pyrimidine compounds as delta opioid receptor modulators
JP5770197B2 (ja) * 2009-10-30 2015-08-26 ヤンセン ファーマシューティカ エヌ．ベー． デルタオピオイド受容体調節因子としてのピラジン
US8394809B2 (en) * 2009-10-30 2013-03-12 Janssen Pharmaceutica, Nv Phenoxy-substituted pyrimidines as opioid receptor modulators
WO2011143425A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2011143419A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
CN102947272A (zh) 2010-05-12 2013-02-27 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的2-氨基吡啶衍生物
WO2011143399A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2013529200A (ja) * 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な化合物
WO2011163527A1 (en) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
KR20140027974A (ko) 2011-04-05 2014-03-07 버텍스 파마슈티칼스 인코포레이티드 Ｔｒａ 키나제의 억제제로서 유용한 아미노피라진 화합물
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP2014520161A (ja) 2011-06-22 2014-08-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
AU2012315615A1 (en) 2011-09-30 2014-04-17 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of ATR kinase
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CA3089792C (en) 2011-09-30 2023-03-14 Vertex Pharmaceuticals Incorporated Treating non-small cell lung cancer with atr inhibitors
IN2014KN00943A (pt) 2011-09-30 2015-08-21 Vertex Pharma
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776422A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071088A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
EP2776419B1 (en) 2011-11-09 2016-05-11 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
DK3486245T3 (da) 2012-12-07 2021-07-19 Vertex Pharma 2-amino-n-(piperidin-1-yl-pyridin-3-yl) pyrazolo[1,5alpha]pyrimidin-3-carboxamid som hæmmer for atr kinase
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
KR101504722B1 (ko) 2013-06-12 2015-03-24 한국화학연구원 카모로놀 화합물을 유효성분으로 포함하는 심혈관 질환의 예방 및 치료용 약학적 조성물
SI3077397T1 (sl) 2013-12-06 2020-02-28 Vertex Pharmaceuticals Inc. 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati
SG10201902206QA (en) 2014-06-05 2019-04-29 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
HUE044280T2 (hu) 2014-06-17 2019-10-28 Vertex Pharma Rosszindulatú daganatok kezelése Chk1- és ATR-gátlók kombinációjával
KR20180054657A (ko) 2015-09-30 2018-05-24 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제 및 atr 저해제의 병용물을 사용한 암 치료 방법
GB201715410D0 (en) 2017-09-22 2017-11-08 Syngenta Participations Ag Improvements in or relating to organic compounds
WO2019119207A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
CN112142716B (zh) * 2020-10-29 2021-08-31 山东新时代药业有限公司 一种5元杂芳基取代的吡嗪衍生物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0868186B1 (en) * 1995-12-21 2005-03-02 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US5798380A (en) * 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
JP3669711B2 (ja) * 1996-08-12 2005-07-13 三菱ウェルファーマ株式会社 Ｒｈｏキナーゼ阻害剤を含有する医薬
ATE529102T1 (de) * 1998-08-17 2011-11-15 Senju Pharma Co Verbindung zur vorbeugung und behandlung von glaukoma
JP4509395B2 (ja) * 1999-04-27 2010-07-21 田辺三菱製薬株式会社 肝臓疾患の予防治療薬
US6348494B1 (en) * 2000-11-21 2002-02-19 American Home Products Corporation Ethers of o-desmethyl venlafaxine
ES2266171T3 (es) * 2000-03-16 2007-03-01 Mitsubishi Pharma Corporation Compuestos de amida y su uso.
JP4776138B2 (ja) * 2000-03-31 2011-09-21 田辺三菱製薬株式会社 腎臓疾患予防・治療剤
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
ES2333586T3 (es) 2001-11-21 2010-02-24 PHARMACIA & UPJOHN COMPANY LLC Derivados de aril 1,4-pirazina sustituidos.
DE60207890T2 (de) * 2001-12-18 2006-08-10 Astrazeneca Ab Neue verbindungen
US7094789B2 (en) * 2002-07-22 2006-08-22 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivatives
CA2496197A1 (en) * 2002-08-20 2004-03-04 Neurogen Corporation 5-substituted-2-arylpyrazines as modulators of crf receptors
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
AU2004224392A1 (en) * 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocyles as sodium channel blockers
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
BRPI0415863A (pt) * 2003-10-27 2007-01-09 Astellas Pharma Inc derivados pirazina e seus usos farmacêuticos
EP1694670A1 (en) * 2003-12-16 2006-08-30 GPC Biotech AG Pyrazine derivatives as effective compounds against infectious diseases
KR20070008674A (ko) * 2004-04-01 2007-01-17 아스테라스 세이야쿠 가부시키가이샤 피라진 유도체, 및 아데노신 길항제로서의 이의 약학적용도

Also Published As

Publication number Publication date
WO2006071548A3 (en) 2006-09-08
EP1830853A2 (en) 2007-09-12
AR053110A1 (es) 2007-04-25
US20060142307A1 (en) 2006-06-29
CN101102773B (zh) 2010-10-27
AU2005322338B2 (en) 2011-06-09
AU2005322338A1 (en) 2006-07-06
CN101102773A (zh) 2008-01-09
ATE519488T1 (de) 2011-08-15
MX2007007797A (es) 2007-08-23
KR20070100952A (ko) 2007-10-15
ZA200704959B (en) 2009-04-29
WO2006071548A2 (en) 2006-07-06
EP1830853B1 (en) 2011-08-10
PL383491A1 (pl) 2008-03-17
US20100216777A1 (en) 2010-08-26
TW200633709A (en) 2006-10-01
KR100994173B1 (ko) 2010-11-15
CA2590261C (en) 2011-08-16
JP2008525453A (ja) 2008-07-17
US20080269249A2 (en) 2008-10-30
HK1104222A1 (en) 2008-01-11
ES2368338T3 (es) 2011-11-16
CA2590261A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
BRPI0519508A2 (pt) análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
MX2010003774A (es) Formulaciones oftalmicas acuosas.
BRPI0613401B8 (pt) composição oftálmica compreendendo derivados de glicocorticoides que penetram seletivamente nos tecidos do segmento posterior
CR10041A (es) Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares
WO2007104541A3 (en) Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
BRPI0606172A2 (pt) métodos e composições para o tratamento de distúrbios oculares
WO2007089375A3 (en) Compositions and methods for regulating complement system
MY159463A (en) Method and composition for treating ocular hypertension and glaucoma
EA201170551A1 (ru) Способы лечения заболеваний глаз
BRPI0516377A (pt) inibição de rnai de ctgf para tratamento de distúrbios oculares
EA201790267A1 (ru) Новые модуляторы киназ
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
EA201790889A1 (ru) Офтальмологический раствор
MX2019008963A (es) Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico.
SG171602A1 (en) Use of antisecretory factors for treating intraocular hypertension
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
AU2018240462A1 (en) Drugs and compositions for the treatment of ocular disorders
BR112017007095A2 (pt) conjugados e derivados de prostaglandina para tratamento de glaucoma e hipertensão ocular

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.